TFPI

TFPI Informations sur la molécule

Nom anglais	Tissue factor pathway inhibitor	Nombre de médicaments commercialisés	2
Nombre de médicaments cliniques	3	Alias de la cible	TFPI，Tissue Factor Pathway Inhibitor，Extrinsic Pathway Inhibitor，TFPI1，LACI，EPI，Anti-Convertin，TFI，Lipoprotein-associated coagulation inhibitor，Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor)
Phase de R&D la plus avancée	Approved

Nom anglais	Tissue factor pathway inhibitor
Alias de la cible	TFPI，Tissue Factor Pathway Inhibitor，Extrinsic Pathway Inhibitor，TFPI1，LACI，EPI，Anti-Convertin，TFI，Lipoprotein-associated coagulation inhibitor，Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor)
Nombre de médicaments commercialisés	2
Nombre de médicaments cliniques	3
Phase de R&D la plus avancée	Approved

TFPI Liste de produits

Attribut
Protein (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
His Tag (1)
Marqueur
Unconjugated (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
TFI-H5226	Human	HEK293	Human TFPI Protein, His Tag (active enzyme)				Ajouter au panier

Quantité totale1

TFPIContexte de la molécule

Tissue factor pathway inhibitor (TFPI) is also known as Extrinsic pathway inhibitor (EPI), Lipoprotein - associated coagulation inhibitor (LACI), is a plasma proteinase inhibitor synthesized by vascular endothelial cells and part of it is associated with glycosaminoglycans of these cells. TFPI is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa) and Thrombin (Factor IIa). TFPI is a secreted protein with a Nterminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a Cterminal basic region. The first K domain inhibits coagulation factor VIIa complexed to tissue factor (TF); The second K domain inhibits factor Xa; The third K domain binds to heparin; The Cterminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces.

TFPIAlias de la molécule

TFPI,LACI,TFPI1,EPI,TFI

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
KN-057	KN-057; KN057	Phase 3 Clinical	Suzhou Alphamab Co Ltd	Hemophilia A; Hemophilia B	Details
MG-1113	MG-1113; MG-1113A	Phase 1 Clinical	GC Biopharma Corp	Hemophilia A	Details
AP-017	AP017; AP-017	Phase 1 Clinical	Anyuan Pharmaceutical Technology (Shanghai) Co Ltd	Hemophilia A; Hemophilia B	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Concizumab	Anti-TFPI; mAb-2021; NNC-0172-2021; NNC-172-2021; mAbTFPI2021; NN-7415; NNC-0172-0000-2021	Approved	Novo Nordisk A/S	Alhemo	Canada	Hemophilia B	Novo Nordisk Canada Inc	2023-04-17	Hemophilia A; Hemophilia B; Hemorrhage	Details
Marstacimab	PF-6741086; PF-06741086	Approved	Pfizer Inc	HYMPAVZI, 友瑞宁	United States	Hemophilia A; Hemophilia B	Pfizer Inc	2024-10-11	Hemophilia A; Hemophilia B; Hemorrhage	Details